Helen Kotanides

Company: Actinium Pharmaceuticals Inc.

Job title: VP Translational Research & Preclinical Development

Seminars:

Advancing the Development of a Pipeline of Differentiated Radiotherapeutics for Cancer 3:15 pm

• Actinium is a leading speciality oncolcoy radiotherapeutics company with a paradigm shifting induction and conditioning agent, Iomab-B, with positive topline results for R/R AML • Actimab-A investigated in multiple R/R AML trials including in combination with Bcl-2 targeted venetoclax and the salvage chemotherapy CLAG-M with latter showing meaningful improvement in response rates and overall…Read more

day: Scientific Program Day Two